Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the U.S. FDA said on Friday.

Roche Holding AG has priced its personalized cancer treatment, Rozlytrek, at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co that was approved last year.

AbbVie Inc has priced its new rheumatoid arthritis treatment at $59,000 a year after gaining U.S. approval on Friday, a big boost for the drugmaker struggling with rising competition for Humira, its blockbuster therapy for the same condition.

The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.

Heart valve systems from Edwards Lifesciences Corp and Medtronic Plc have been approved for use in a condition that restricts blood flow from the heart in patients at low-risk of death linked to open-heart surgeries, the FDA said on Friday.

DAKAR, Aug 16 (Thomson Reuters Foundation) - Ebola's spread to a new part of Democratic Republic of Congo is a disturbing sign that health workers are failing to keep track of high-risk people on the move, aid agencies said on Friday.

The U.S. Food and Drug Administration on Friday approved AbbVie Inc's new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster flagship therapy Humira faces competition.

UBS Group has hired Seth Damergy to head its medical device and technology investment banking practice in the Americas, according to an internal memo seen by Reuters, the contents of which were confirmed by a bank spokeswoman.

Roche Holding AG priced at about $204,560 a year its personalized cancer treatment, Rozlytrek, which targets tumors with specific genetic mutations, the Swiss drugmaker said.

The U.S. Food and Drug Administration said on Friday it had approved Celgene Corp's treatment, Inrebic, for certain forms of bone marrow cancer.